Celltrion deal shows potential beyond biosimilars

1 June 2018
2019_biotech_test_vial_discovery_big

South Korean company Celltrion Healthcare (KRX:068270) is already proving itself to be one of the leaders globally in biosimilar drug development, but a new deal is a sign of its potential as a developer of new biopharmaceuticals.

The company has signed an agreement with Seoul-based Yonsei University Health System on the joint development and license-in of Fc-Saxatilin, a candidate drug for ischemic strokes, in a bid to develop new drugs for cerebrovascular diseases.

They will conduct joint development for the optimization of the Fc-Saxatilin molecule, after which Celltrion will have an option for the exclusive worldwide license to conduct clinical trials, to obtain approvals, and to commercialize the drug.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology